Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
Minimalist illustration of a drug compound and neural network

Jul 7, 2026

Insilico SK Bio Secures $2.5B AI Drug Discovery Milestone Deal

Insilico SK Bio has secured a transformative partnership with SK Biopharmaceuticals, aimed at addressing neuroimmune central nervous system disorders, with a total potential value exceeding $2.5 billion. This significant milestone highlights the growing impact of AI in drug discovery, particularly in the context of a rapidly evolving competitive landscape.The partnership includes an upfront payment of $18 million, with additional milestone payments contingent on the successful development and co
A minimalist illustration of a pill against a dark background.

Jul 7, 2026

Drug discovery AI moves beyond hype to an R&D productivity test

AI is transitioning from hype to a pragmatic tool in drug discovery, helping to streamline specific processes rather than replacing entire development pipelines.The pharmaceutical and biotechnology sectors are increasingly recognizing AI's value in addressing particular challenges in drug development, such as target identification, protein structure prediction, and clinical trial design. This shift in perspective has led to major companies pursuing collaborations with AI firms, as well as invest
A glass vial with a colorful drug compound on a lab bench

Jul 4, 2026

Anthropic enters drug development arena

Anthropic, known for its Claude AI system, is making a significant move into the pharmaceutical sector, aiming to develop software for drug discovery.The company, led by Eric Kauderer-Abrams in its life sciences division, intends to market its AI solutions to pharmaceutical manufacturers, positioning itself against established competitors such as Isomorphic Labs and major players like AstraZeneca and GSK. This shift reflects a growing trend of leveraging artificial intelligence in drug developme
A minimalist illustration of a pill and a molecule on a solid background.

Jul 4, 2026

Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable

Anthropic is embarking on innovative drug discovery initiatives aimed at neglected diseases, a sector often overlooked by major pharmaceutical companies due to perceived unprofitability.The organization is focusing on early-stage drug development, aligning its efforts with its nonprofit mission. This strategy is expected to enhance Anthropic's AI models and tools, providing valuable insights from direct experience in drug discovery. The announcement coincided with the launch of "Claude Science,"
A minimalist illustration of a pill capsule representing drug development.

Jul 4, 2026

Anthropic wants to develop its own drugs

Anthropic is venturing into drug development with its new AI platform, Claude Science, aimed at enhancing scientific discovery.During the recent event “The Briefing: AI for Science,” Anthropic unveiled Claude Science, which integrates various scientific tools and datasets into a cohesive environment, enabling users to generate visuals and figures efficiently. The company emphasized the potential of AI to significantly expedite scientific advancements and healthcare solutions, boasting a range of
A minimalist illustration of a pill symbolizing drug discovery.

Jul 3, 2026

Insilico Medicine, Takeda Partner to Advance AI-Driven Drug Discovery

Insilico Medicine has formed a strategic partnership with Takeda to enhance drug discovery through artificial intelligence.In this collaboration, Insilico Medicine will spearhead the AI-driven discovery of new drug candidates utilizing its Pharma.AI platform, while Takeda will manage the clinical development and commercialization of selected candidates. The partnership aims to identify drug candidates that can stand out in Takeda's key therapeutic areas, focusing on improving both efficacy and s
A test tube with green liquid in a dimly lit lab

Jul 3, 2026

Hyderabad Startup Harnesses AI & Nanotechnology to Advance Autoimmune Skin Disorders & Wound Care

A Hyderabad-based startup, Acubiosys, is leveraging artificial intelligence and nanotechnology to develop innovative therapies for autoimmune skin disorders and wound care. By integrating these advanced technologies with biomedical research, the company aims to create targeted, effective treatments for chronic conditions.Acubiosys, incubated at the BRIC-CDFD Technology Incubator, employs AI algorithms to analyze extensive botanical databases and conducts three-dimensional molecular modeling to s
A close-up of a nanoparticle on a lab surface, symbolizing innovative psoriasis treatment.

Jul 3, 2026

Hyderabad-based startup harnesses AI to develop treatment for psoriasis

A Hyderabad-based startup, Acubiosys Private Limited, is leveraging artificial intelligence and nanotechnology to create innovative treatments for psoriasis and diabetic wounds.Founded within the BRIC-Centre for DNA Fingerprinting and Diagnostics incubator, Acubiosys focuses on developing evidence-based therapeutics for autoimmune conditions and skin disorders. Their approach combines AI-assisted drug discovery with nanotechnology, aiming to create safer, more targeted treatments for challenging
A minimalist representation of a drug compound molecule in flat design.

Jul 2, 2026

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Artificial intelligence (AI) is revolutionizing drug discovery, significantly reducing the time required for development and enhancing the potential for successful market entries.The traditional drug development process is notoriously lengthy, often spanning 10 to 15 years with a staggering 90% of candidates failing to gain approval. However, AI is transforming this landscape by optimizing drug discovery, allowing researchers to analyze millions of molecular combinations in weeks rather than yea
A minimalist illustration of a pill and capsule against a dark background.

Jul 2, 2026

AI-driven Drug Discovery Faces 2026 Test

The landscape of AI-driven drug discovery is poised for a significant evaluation in 2026, as a cohort of AI-generated drugs is set to enter critical Phase 3 trials.In a recent analysis by Michael Santoro, a business ethics professor, the implications of substantial investments in AI for drug discovery are scrutinized. Notable examples include Xaira’s ambitious $1 billion launch and Alphabet’s Isomorphic Labs, which secured $600 million in funding. Santoro references a Boston Consulting Group stu
A minimalist illustration of a pill bottle and an AI brain in flat design.

Jul 2, 2026

How Indian Pharma Firms Are Using AI to Cut Drug Discovery Time

Indian pharmaceutical companies are increasingly leveraging artificial intelligence (AI) to enhance drug discovery processes, aiming to cut down the traditionally lengthy and costly timeline associated with bringing new medications to market.The pharmaceutical sector faces significant challenges due to the lengthy and expensive nature of drug development, which often spans over a decade and costs billions. AI and machine learning technologies are now being employed to streamline this process, en
A glass vial and syringe in a dimly lit lab setting

Jul 2, 2026

Indian pharma uses AI to cut development time and costs

AI is revolutionizing the pharmaceutical landscape in India by significantly reducing the time and costs associated with drug development. Traditionally, the drug development process in India could span over a decade and incur substantial financial burdens. However, the integration of artificial intelligence and machine learning is transforming this paradigm. Rather than displacing the workforce, Indian pharmaceutical companies are leveraging AI as a collaborative tool to tackle complex scientif